RECRUITING

Interventions for Postoperative Delirium: Biomarker-3

Talk to us

Conditions

Delirium

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The IPOD-B3 study aims to characterize the relationship between premorbid brain activity and postoperative delirium in patients undergoing major surgery. This is a expansion of the NeuroVISION Bolt-On study, NCT01980511.

Official Title

Interventions for Postoperative Delirium: Biomarker-3

Quick Facts

Study Start:2017-02-13
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03124303

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥65 years
  2. * Anticipated length of hospital stay of at least 2 days after surgery that occurs under general or neuraxial anesthesia
  3. * Written Informed Consent for potential participation prior to surgery
  1. * Contraindication to EEG
  2. * Unable or unwilling to attend the follow-up appointments
  3. * Documented history of dementia
  4. * Deemed incapable of providing consent by surgical team
  5. * Residing in a nursing home
  6. * Undergoing intracranial surgery
  7. * Unable to complete neurocognitive testing due to language, vision or hearing impairment
  8. * Unable to communicate with the research staff due to language barriers
  9. * For optional MRI portion of the study: Contraindication to MRI (e.g., implanted devices not safe for MRI studies, claustrophobia, unable to lie flat or still)

Contacts and Locations

Study Contact

David Kunkel, BS
CONTACT
608-262-6469
dkunkel@wisc.edu
Frankie Ingram, BS
CONTACT
608-262-6469
fingram@wisc.edu

Principal Investigator

Robert Pearce, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

University of Wisconsin-Madison
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Robert Pearce, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-02-13
Study Completion Date2025-12

Study Record Updates

Study Start Date2017-02-13
Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

  • Delirium